Drug Trial Radar · NCT06985706
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
264
Planned (sponsor's estimate)
Start
May 19, 2025
Primary completion
Nov 30, 2028
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- Belfast Health and Social Care TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Queen's University, Belfast
- First posted
- May 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The macula is the centre of the retina; it gives central sight, colour and fine detail. People with diabetes may develop diabetic macular oedema (DMO). In DMO, fluid leaks from blood vessels and builds up at the macula, causing sight loss. DMO can be mild or severe; this is determined by measuring, in microns (µm), how thick the macula is. One µm is one-thousandth of a millimetre. People presenting with mild DMO (macula less than 400 µm thick; normally it is around 250 µm but varies with sex and ethnicity) are offered macular laser treatment. Laser works well for these patients. Subthreshold micropulse laser (SML), which does not damage the macula, works as well as standard laser, which produces a burn, and is cost-effective. However, many people present with severe DMO (macula 400 µm or thicker) where the laser does not work well. The standard treatment is eye injections of anti-VEGFs. VEGF stands for vascular endothelial growth factor. VEGF is high in eyes with DMO and causes blood vessel leakage. Anti-VEGFs block VEGF. They are given monthly to begin with, then every 2-3 months for months or years until DMO clears. In many patients DMO comes back after clearing and anti-VEGFs need to be re-started most often monthly initially again. To improve the care of people with severe DMO this study will compare the current standard care (anti-VEGFs alone) with a strategy in which patients begin with an anti-VEGF but switch to SML once the macula is less than 400 µm thick. Patients aged over 18 years with type 1 or type 2 diabetes and severe DMO can participate. They are randomly allocated either anti-VEGFs alone or anti-VEGFs then SML when the macula is less than 400 µm thick.
Conditions
- Severe Diabetic Macular Oedema
Interventions
Subthreshold Micropulse Laser (SML)Procedure
SML will be applied in line with the DAME Guideline and follow the DAME participant pathway.
Anti-VEGF Monotherapy (standard care)Drug
Anti-VEGFs including ranibizumab and biosimilars, aflibercept, faricimab, and brolucizumab will be used, as per the standard of care at participating sites. The anti-VEGF should be administered in line with the summary of product characteristics (SmPC).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best-Corrected Visual Acuity (BCVA)Time frame: 104 weeks after randomisation
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Bedford Hospital
Bedford, United Kingdom · Recruiting
The Royal Hospitals Belfast
Belfast, United Kingdom · Recruiting
Birmingham and Midland Eye Centre
Birmingham, United Kingdom · Recruiting
Sussex Eye Hospital
Brighton, United Kingdom · Recruiting
Bristol Eye Hospital
Bristol, United Kingdom · Recruiting
Frimley Park Hospital
Camberley, United Kingdom · Recruiting
University Hospital of Wales
Cardiff, United Kingdom · Not yet recruiting
Gloucestershire Royal Hospital
Gloucester, United Kingdom · Recruiting
Hull Royal Infirmary
Hull, United Kingdom · Recruiting
Royal Liverpool University Hospital
Liverpool, United Kingdom · Recruiting
Central Middlesex Hospital
London, United Kingdom · Recruiting
Chelsea and Westminster Hospital
London, United Kingdom · Recruiting
Kings College Hospital
London, United Kingdom · Recruiting
Moorfields Eye Hospital
London, United Kingdom · Recruiting
James Cook Hospital
Middlesbrough, United Kingdom · Recruiting
Royal Gwent Hospital
Newport, United Kingdom · Recruiting
Queen's Medical Centre
Nottingham, United Kingdom · Not yet recruiting
University Hospital Southampton
Southampton, United Kingdom · Recruiting
Sunderland Eye Hospital
Sunderland, United Kingdom · Recruiting
Singleton Hospital
Swansea, United Kingdom · Recruiting
Torbay Hospital
Torquay, United Kingdom · Recruiting
Hillingdon Hospital
Uxbridge, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.